+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Migraine Drugs Market by Drug Class, Route of Administration, Distribution Channel, Indication, Patient Age Group - Global Forecast to 2030- Product Image
Migraine Drugs Market by Drug Class, Route of Administration, Distribution Channel, Indication, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Migraine Drugs Market by Drug Class, Route of Administration, Distribution Channel, Indication, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968814
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The migraine drugs market is undergoing rapid transformation as new therapies emerge, regulatory frameworks evolve, and digital healthcare integration accelerates. For senior leaders, a clear understanding of this market’s complex dynamics and key growth drivers is critical when considering investment, R&D priorities, and competitive positioning.

Market Snapshot: Migraine Drugs Market Growth

The Migraine Drugs Market grew from USD 5.48 billion in 2024 to USD 6.39 billion in 2025. It is expected to continue growing at a CAGR of 15.88%, reaching USD 13.28 billion by 2030. Rapid expansion is being driven by an increased prevalence of migraine cases, the introduction of advanced preventive and acute treatments, and enhanced healthcare awareness. Pharmaceutical innovation, particularly within targeted biologics and non-vasoconstrictive small molecules, continues to shape both the supply landscape and healthcare outcomes.

Scope & Segmentation

This report provides in-depth analysis across the entire spectrum of migraine therapeutics, enabling stakeholders to benchmark key trends and opportunities.

  • Drug Classes: CGRP monoclonal antibodies, ditans, ergot derivatives, gepants, NSAIDs, triptans
  • Therapeutic Molecules: Includes eptinezumab, erenumab, fremanezumab, galcanezumab, lasmiditan, dihydroergotamine, ergotamine, atogepant, rimegepant, ubrogepant, diclofenac, ibuprofen, naproxen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
  • Routes of Administration: Injectable (intravenous, subcutaneous), nasal, oral (capsule, tablet), topical, transdermal
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • Indications: Acute treatment and preventive treatment
  • Patient Age Groups: Adult, pediatric (adolescents, children, neonates)
  • Regions & Countries: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including EU5, United Kingdom, Russia, UAE, Saudi Arabia, South Africa, Nordic countries, others), Asia-Pacific (China, India, Japan, Australia, South Korea, and more)
  • Leading Companies Analyzed: AbbVie Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, H. Lundbeck A/S, Biohaven Pharmaceutical Holding Company Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc.

Key Takeaways from the Migraine Drugs Market

  • Innovation in targeted therapies, especially CGRP inhibitors and next-generation small molecules, is shifting treatment away from traditional approaches and driving adoption among healthcare providers and patients.
  • Digital therapeutics and telemedicine are now pivotal, allowing real-time symptom tracking, personalized regimen adjustments, and broadening access to advanced migraine care globally.
  • Mergers and strategic partnerships are accelerating pipeline diversity and competitive differentiation, with established firms acquiring biotech innovations to remain at the forefront of therapeutic offerings.
  • Patient-centric segment analysis reveals growing attention to pediatric populations, compelling manufacturers to develop specific formulations and dosing protocols for younger cohorts.
  • Regional market access remains heterogeneous, shaped by local regulatory pathways, reimbursement mechanisms, and healthcare infrastructure, with Asia-Pacific and parts of Latin America representing significant untapped growth potential.
  • Cost pressures linked to shifting supply chain models and payer negotiations create both risks and incentives for strategic operational adjustments across the value chain.

Tariff Impact: Managing Supply Chain Complexity

New US tariff structures on pharmaceutical imports in 2025 have introduced greater complexity to migraine drug sourcing and pricing strategies. Manufacturers are pursuing local production alliances, optimizing procurement settings, and adjusting distribution tactics to offset increased input costs. Payer organizations continue to weigh these factors when reviewing coverage decisions, especially for high-value biologics and emerging small-molecule therapies.

Methodology & Data Sources

The findings are based on a robust methodology comprising primary interviews with clinical and industry stakeholders, including neurologists, payers, and executives, as well as secondary research from peer-reviewed journals, regulatory documentation, and annual company reports. Data validation employed triangulation and multi-tier expert reviews, enhancing the overall reliability and accuracy of insights presented.

Why This Migraine Drugs Market Report Matters

  • Enables effective decision-making by distilling critical trends, competitive dynamics, and regional nuances, allowing leaders to position portfolios for growth and resilience.
  • Assists in identifying and prioritizing investment in high-impact segments, from innovative drug classes to emerging patient populations and regional demand hotspots.
  • Supports strategic responses to changing regulatory, pricing, and supply-chain landscapes, crucial for maintaining access and managing risk.

Conclusion

As the migraine drugs market transforms, industry stakeholders who stay informed and adaptable will be best equipped to capture growth and shape the future of therapeutic care. Leveraging these insights, companies can foster innovation, optimize strategy, and meet evolving healthcare requirements.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Migraine Drugs Market, by Drug Class
8.1. Introduction
8.2. Cgrp Monoclonal Antibodies
8.2.1. Eptinezumab
8.2.2. Erenumab
8.2.3. Fremanezumab
8.2.4. Galcanezumab
8.3. Ditans
8.3.1. Lasmiditan
8.4. Ergot Derivatives
8.4.1. Dihydroergotamine
8.4.2. Ergotamine
8.5. Gepants
8.5.1. Atogepant
8.5.2. Rimegepant
8.5.3. Ubrogepant
8.6. Nsaids
8.6.1. Diclofenac
8.6.2. Ibuprofen
8.6.3. Naproxen
8.7. Triptans
8.7.1. Almotriptan
8.7.2. Eletriptan
8.7.3. Frovatriptan
8.7.4. Naratriptan
8.7.5. Rizatriptan
8.7.6. Sumatriptan
8.7.7. Zolmitriptan
9. Migraine Drugs Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Nasal
9.4. Oral
9.4.1. Capsule
9.4.2. Tablet
9.5. Topical
9.6. Transdermal
10. Migraine Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Migraine Drugs Market, by Indication
11.1. Introduction
11.2. Acute Treatment
11.3. Preventive Treatment
12. Migraine Drugs Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
12.3.1. Adolescents
12.3.2. Children
12.3.3. Neonates
13. Americas Migraine Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Migraine Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Migraine Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Amgen Inc.
16.3.3. Novartis AG
16.3.4. Eli Lilly and Company
16.3.5. H. Lundbeck a/S
16.3.6. Biohaven Pharmaceutical Holding Company Ltd.
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MIGRAINE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. MIGRAINE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. MIGRAINE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 95. CANADA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. CANADA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 97. CANADA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 98. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 99. CANADA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 100. CANADA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 101. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 102. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 104. CANADA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. CANADA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 109. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 118. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 180. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 184. GERMANY MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 186. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 189. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. GERMANY MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 194. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. FRANCE MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 198. FRANCE MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 199. FRANCE MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 200. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 201. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. FRANCE MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 203. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 204. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. FRANCE MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 222. ITALY MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. ITALY MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 224. ITALY MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 225. ITALY MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 226. ITALY MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 227. ITALY MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 228. ITALY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 229. ITALY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. ITALY MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. ITALY MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 232. ITALY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ITALY MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. ITALY MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. ITALY MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 236. SPAIN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. SPAIN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. SPAIN MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 239. SPAIN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 240. SPAIN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 241. SPAIN MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 242. SPAIN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 243. SPAIN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 245. SPAIN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 246. SPAIN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. SPAIN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. SPAIN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. SPAIN MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 292. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. DENMARK MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 295. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 296. DENMARK MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 297. DENMARK MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 298. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 299. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. DENMARK MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 301. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 302. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. DENMARK MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 304. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 312. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 313. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 315. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 316. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 319. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 320. QATAR MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. QATAR MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 322. QATAR MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 323. QATAR MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 324. QATAR MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 325. QATAR MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 326. QATAR MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 327. QATAR MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. QATAR MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 329. QATAR MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 330. QATAR MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. QATAR MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 332. QATAR MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. QATAR MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 334. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 335. FINLAND MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 336. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 337. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 338. FINLAND MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 339. FINLAND MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 340. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 341. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. FINLAND MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 344. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. FINLAND MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 346. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 347. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 348. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 349. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 350. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2030 (USD MILLION)
TABLE 351. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 352. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2030 (USD MILLION)
TABLE 353. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2030 (USD MILLION)
TABLE 354. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 355. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 356. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 357. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 358. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 359. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 360. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 361. SWEDEN MIGRAINE DRUGS MARKET SIZE, BY PE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Migraine Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.28 Billion
Compound Annual Growth Rate15.8%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment (Acute, Preventive), Therapeutic Class, Route of Administration, Age Group (Pediatric, Adult, Geriatric), Availability, Region, with Growth Forecasts, 2025-2030 - Product Image

Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment (Acute, Preventive), Therapeutic Class, Route of Administration, Age Group (Pediatric, Adult, Geriatric), Availability, Region, with Growth Forecasts, 2025-2030

  • Report
  • 159 Pages
  • Global
From
Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Migraine Drugs - Global Strategic Business Report - Product Image

Migraine Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From

About the Migraine Drug Market

The Migraine Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Migraine drugs are used to treat the symptoms of migraine headaches, such as nausea, vomiting, and sensitivity to light and sound. These drugs can be divided into two categories: abortive and preventive. Abortive drugs are taken at the onset of a migraine attack to reduce the severity of symptoms, while preventive drugs are taken on a regular basis to reduce the frequency of migraine attacks. Common abortive drugs include triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs (NSAIDs). Common preventive drugs include beta-blockers, anticonvulsants, and serotonin receptor agonists. Some companies in the Migraine Drug market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Allergan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.